Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - STOCKHEAD.COM.AU - A La Une - 09/Sep 04:15
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Articles similaires
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Dimerix first patient completes Phase 3 trial and enters into long-term DMX-200 Open Label Extension study
stockhead.com.au - 10/Sep 23:38
Dimerix has enrolled the first patient into the Open Label Extension study for its kidney disease drug candidate DMX-200 after ...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
haei.org - 06/Sep 18:54
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma
pharmabiz.com - 14/Sep 23:19
Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 12/Sep 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 12/Sep 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Les derniers communiqués
-
Aucun élément